Literature DB >> 9309996

Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease.

N Roger1, J A Barberà, J Roca, I Rovira, F P Gómez, R Rodriguez-Roisin.   

Abstract

Patients with chronic obstructive pulmonary disease (COPD) may develop hypoxemia and pulmonary hypertension when exercising. To investigate whether inhaled nitric oxide (NO), a selective pulmonary vasodilator, modifies the changes induced by exercise in pulmonary hemodynamics and gas exchange in COPD, we studied nine patients (FEV1, = 39 +/- 2% predicted), at rest and at submaximal exercise, during breathing of room air and NO (40 ppm). NO inhalation decreased pulmonary artery pressure (Ppa) both at rest and during exercise (analysis of variance [ANOVA] p < 0.05). However, the effect of NO on PaO2 was different at rest than during exercise. At rest, NO decreased PaO2 from 72 +/- 3 mm Hg to 65 +/- 2 mm Hg, due to an increase in ventilation-perfusion (VA/Q) inequality (dispersion of blood flow distribution from 0.9 +/- 0.1 to 1.1 +/- 0.1). During exercise, PaO2 decreased during breathing of room air (-5 +/- 3 mm Hg), whereas it remained essentially unchanged during inhalation of NO (+2 +/- 3 mm Hg), with both changes being significantly different (p < 0.05). VA/Q relationships improved during exercise during breathing of both room air and NO, as a result of a reduction in the dispersion of ventilation distribution. Moreover, NO administered on exertion contributed to redistribute blood flow from alveolar units with low VA/Q ratios to units with normal ratios (p < 0.05). We conclude that in patients with COPD, the inhalation of NO during exercise moderately reduces pulmonary hypertension, and that in contrast with the effects of such inhalation at rest, it may prevent the exercise-associated decrease of PaO2. This effect is probably explained by a preferential distribution of inhaled NO during exercise to well-ventilated alveolar units with faster time constants and normal VA/Q ratios.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309996     DOI: 10.1164/ajrccm.156.3.9611051

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  24 in total

Review 1.  Exhaled nitric oxide during exercise.

Authors:  A W Sheel; J Road; D C McKenzie
Journal:  Sports Med       Date:  1999-08       Impact factor: 11.136

2.  Inhaled nitric oxide delivery and monitoring.

Authors:  F J Montgomery; A D Berssenbrugge
Journal:  J Clin Monit Comput       Date:  1999-07       Impact factor: 2.502

3.  Use of nitric oxide inhalation in chronic obstructive pulmonary disease.

Authors:  K Ashutosh; K Phadke; J F Jackson; D Steele
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 4.  Inhaled pulmonary vasodilators: a narrative review.

Authors:  Kai Liu; Huan Wang; Shen-Ji Yu; Guo-Wei Tu; Zhe Luo
Journal:  Ann Transl Med       Date:  2021-04

5.  Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.

Authors:  Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

6.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

7.  Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.

Authors:  Hossein A Ghofrani; Gerd Staehler; Ekkehard Grünig; Michael Halank; Veselin Mitrovic; Sigrun Unger; Wolfgang Mueck; Reiner Frey; Friedrich Grimminger; Ralph T Schermuly; Juergen Behr
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

Review 8.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 9.  Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 10.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.